JPM26: Biotech’s M&A lift, the ‘new’ Biogen and Merck’s $70B target

Within that pipeline, Biogen has five experimental drugs in late-stage testing that it classifies as programs with “significant commercial potential.” The list includes two potential lupus therapies, named litifilimab and dapirolizumab pegol, as well as an immune system-regulating antibody that the company got ahold of through a $1.2 billion acquisition . That antibody, “felzartamab,” is being evaluated against several kidney illnesses.The executive team “has been out meeting with investors and analysts on ...